Key result
Sildenafil improves erectile function and quality of life over placebo in symptomatic heart failure.
RCT (n=35)
Answers are grounded in this paper and cite their sources.
BACKGROUND: Erectile dysfunction (ED) is common in patients with congestive heart failure (CHF) and is often associated with symptoms of depression. Although sildenafil citrate, a phosphodiesterase 5 inhibitor, is effective in treating ED, its use is considered a relative contraindication in CHF. We hypothesized that sildenafil is a safe and effective treatment for ED in patients with New York Heart Association classes II and III CHF and that treatment of ED will improve symptoms of depression and enhance perceived of quality of life. METHODS: We studied 35 patients in a prospective, placebo-controlled, crossover trial for 12 weeks. Inclusion required a history of chronic ED and absence of ischemia (negative results from exercise stress test or nuclear perfusion scan) or nitrate use. The tolerability of sildenafil citrate was established by monitoring the ambulatory blood pressure for 4 hours after a single 50-mg dose. Improvement in ED, the primary end point, was assessed using the International Index of Erectile Function survey. The effect of improved erectile function on quality of life and mood was assessed using the Minnesota Living With Heart Failure Questionnaire, the Beck Depression Index, and the Center for Epidemiological Studies-Depression Scale. RESULTS: Sildenafil caused a mean +/- SEM asymptomatic decrease in blood pressure of 6 +/- 3 mm Hg, and no patient experienced symptomatic hypotension or other significant adverse effects. Sildenafil improved the International Index for Erectile Function (P<.001) and both sets of depression scores. The Living With Heart Failure Questionnaire index also improved with sildenafil (P =.02). CONCLUSION: Sildenafil is a safe and effective treatment for ED in men with New York Heart Association classes II and III CHF and provides relief of depressive symptoms, explaining an improvement in the perception of quality of life.
No takes yet. Share an insight, caveat, or question.
Webster et al. (2004) conducted an RCT in Congestive Heart Failure and Erectile Dysfunction (n=35). Sildenafil vs. Placebo was evaluated on Improvement in erectile dysfunction assessed using the International Index of Erectile Function survey (p=<.001). Sildenafil safely improved erectile function (P<.001) and quality of life (P=.02) in men with NYHA class II and III congestive heart failure, compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: